Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NY-ESO-1/CTAG1A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (pMHC) | NY-ESO-1(peptide)-HLA-A*02:01 Complex High purity (>95%), Endotoxin <1EU/ug. Native folding verified. |
View NY-ESO-1 Products |
| Antigen (Full-length) | CTAG1A Full-Length Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. HEK293 or E. coli expressed. Sequence verified. |
View NY-ESO-1 Products |
| Gene Delivery | NY-ESO-1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for TCR-T expression. |
View NY-ESO-1 Products |
| Benchmark Ab | Anti-NY-ESO-1 (Clone E978 or Benchmark TCR/Antibody) Recombinant positive control for IHC/ICC/binding assays. Sequence verified. |
View NY-ESO-1 Products |
| Validator | NY-ESO-1 siRNA Set For knockdown verification and specificity controls. |
View NY-ESO-1 Products |
| Related Target A | HLA-A*02:01 Crucial MHC presentation complex for NY-ESO-1 peptide targeting. |
View HLA-A0201 Products |
| Related Target B | MAGE-A4 Synergistic Cancer-Testis Antigen for broad-spectrum solid tumor coverage. |
View MAGE-A4 Products |
| Related Target C | PRAME Alternative CTA target with distinct HLA restriction. |
View PRAME Products |
| Related Target D | CTAG1B (LAGE-1) Close homolog requiring cross-reactivity screening. |
View CTAG1B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Accurate pMHC Targeting Validation | Recombinant HLA/Peptide complexes available with >95% purity and native folding, suitable for SPR/BLI affinity measurement. |
| TCR Cross-Reactivity Screening (LAGE-1) | Homolog panel proteins (CTAG1A vs CTAG1B) with >95% purity, strictly verified by mass spec and sequence. |
| Off-target CTA Screening | Extended CTA panel (MAGE-A4, PRAME) available for counter-screening to exclude false positives. |
| Lack of Controls | Clinical Benchmark Antibodies/TCRs and siRNA included for precise affinity ranking and specificity checks. |
| False Positives | Validated siRNA included for specificity checks in target-negative cell models. |
Live NY-ESO-1/CTAG1A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NY-ESO-1 therapeutics is intensifying, with major players shifting focus from traditional vaccines to advanced TCR-T cell therapies and TCR-bispecifics (TCEs). Because NY-ESO-1 is an intracellular cancer-testis antigen, targeting relies heavily on MHC presentation. As first-generation therapies (e.g., Adaptimmune's afami-cel) reach the clinic, the next wave of R&D is targeting off-the-shelf bispecific modalities and overcoming the immunosuppressive tumor microenvironment in solid tumors like synovial sarcoma and melanoma.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T Cell Therapy | Adaptimmune, GSK, Immatics | Synovial Sarcoma, Melanoma | TCR Affinity Optimization (Need precise pMHC complexes, lentiviral cell lines) |
| TCR-Bispecifics (ImmTACs) | Immunocore, Immatics | Solid Tumors, Uveal Melanoma | Cross-reactivity validation (Need off-target homolog proteins, stable HLA-restricted targets) |
| Therapeutic Vaccine | Bavarian Nordic, BioNTech, GSK | NSCLC, Ovarian Cancer, Multiple Solid Tumors | Immunogenicity Assessment (Need High-Purity Recombinant Antigens) |
| CAR-T | Memorial Sloan Kettering | Myeloma (in combo) | Target expression validation (Need specific antibodies, target-positive cell lines) |